First evaluation of [68Ga]Ga-NOTA-(TMVP1)2 for imaging VEGFR-3 in ovarian cancer patients
To evaluate the safety and VEGFR-3 imaging effects of [<sup>68</sup>Ga]Ga-NOTA-(TMVP1)<sub>2</sub> in ovarian cancer patients. 13 patients with ovarian cancer were recruited and underwent radionuclide imaging with [<sup>68</sup>Ga]Ga-NOTA-(TMVP1)<sub>2</sub>. The safety of [<sup>68</sup>Ga]Ga-NOTA-(TMVP1)<sub>2</sub> was assessed in vivo (including vital signs, biochemical indices, ECG, allergic reactions, etc.) and its imaging effect on VEGFR-3 was explored. A total of 1 patient with primary ovarian cancer and 12 patients with recurrent ovarian cancer, with an age range of 41-54 years, were included in the study. 13 ovarian cancer patients had a total of 49 <sup>18</sup>F-FDG-positive lesions, 63.3% of which were positive for [<sup>68</sup>Ga]Ga-NOTA-(TMVP1)<sub>2</sub>. The higher expression of VEGFR-3 in [<sup>68</sup>Ga]Ga-NOTA-(TMVP1)<sub>2</sub>-positive ovarian cancer lesions was found by immunohistochemical staining, which was positively correlated. Meanwhile, [<sup>68</sup>Ga]Ga-NOTA-(TMVP1)<sub>2</sub> is a safe radiotracer as no significant side effects have been found in the human. In conclusion, [<sup>68</sup>Ga]Ga-NOTA-(TMVP1)<sub>2</sub> enables precise molecular imaging of VEGFR-3 in ovarian cancer patients with a favourable safety profile, providing a new tool for the in vivo assessment of VEGFR-3 in ovarian cancer.
Authors
- Xi Chen (ORCID: https://orcid.org/0000-0003-2860-1978)
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- American Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-01-01
- DOI
- https://doi.org/10.62347/fyyb3942
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00